

Vancomycin – New formulation approval

- On February 19, 2019, [Xellia Pharmaceuticals announced](#) the FDA approval of [vancomycin](#) premixed injection.
- Vancomycin is approved in adult and pediatric patients (1 month and older) for the treatment of susceptible organisms in the following:
 - Septicemia
 - Infective endocarditis
 - Skin and skin structure infections
 - Bone infections
 - Lower respiratory tract infections
 - Consult the vancomycin drug label for details about the susceptible organisms.
- Vancomycin injection, ready to use (RTU) is a proprietary formulation of vancomycin, provided as a premixed solution in single-dose flexible bags, stable at room temperature for 16 months.
- Vancomycin is also available generically as a [capsule](#) and an [intravenous solution for reconstitution](#), and a brand oral solution ([Firvanq™](#)).
 - Oral vancomycin capsules and Firvanq are indicated for the treatment of *Clostridium difficile*-associated diarrhea (CDAD) and enterocolitis caused by *Staphylococcus aureus* (including methicillin-resistant strains).
 - Vancomycin intravenous solution carries the same indications as vancomycin premixed injection. This formulation may also be used orally for CDAD and enterocolitis.
- The FDA approval of this novel vancomycin formulation was obtained on the basis of more than 60 non-clinical experiments, including studies to confirm that the new formulation does not adversely impact the efficacy profile of the active ingredient, vancomycin.
- Vancomycin carries a boxed warning for risk of embryo-fetal toxicity due to excipients.
- Additional warnings and precautions of vancomycin include infusion reaction, nephrotoxicity, ototoxicity, CDAD, hemorrhagic occlusive retinal vasculitis, neutropenia, phlebitis and other administration site reactions, and development of drug-resistant bacteria.
- The most common adverse reactions of vancomycin use were anaphylaxis, “red man syndrome”, acute kidney injury, hearing loss, neutropenia.
- The recommended adult dose of vancomycin is 2 grams intravenously (IV) divided either as 500 mg every 6 hours or 1 gram every 12 hours infused over 60 minutes or greater.
 - The recommended pediatric dose of vancomycin is 10 mg/kg per dose IV every 6 hours infused over a period of at least 60 minutes.
 - This formulation of vancomycin injection should only be used in patients who require the entire (500 mg, 1 gram, 1.5 grams or 2 grams) dose and not any fraction thereof.
 - This formulation of vancomycin injection should not be used orally.

- Xellia Pharmaceuticals' launch plans for vancomycin injection are pending. Vancomycin RTU will be available as 500 mg in 100 mL, 1 gram in 200 mL, 1.5 grams in 300 mL, and 2 grams in 400 mL of liquid in single-dose flexible bags.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.